Subscribe to the BioNews newsletter for free

Advanced Search

Search for
The Progress Educational Trust (PET), informing debate on assisted conception and genetics

Like the Progress Educational Trust on Facebook



EVENTS

Relative Risk: Breast Cancer and Genetics

Progress Educational Trust
Darwin Lecture Theatre, Darwin Building, University College London, Malet Place, London WC1E 6BT
03 April 2014 6.30pm-8.30pm
This public event was organised by the Progress Educational Trust (PET) at University College London, and was supported by the Wellcome Trust. The event marked the launch of the PET project 'Breast Cancer: Chances, Choices and Genetics' (which continued with the succeeding events 'Risk Assessment: Breast Cancer, Prediction and Screening', 'Risk Management: Breast Cancer, Business and Patents' and 'Breast Cancer Risk: Facts, Fictions and the Future').
A podcast produced by James Brooks, in which he interviews members of the speaker panel, can be listened to using the player below or alternatively can be downloaded by clicking here (.mp3 17.6MB).
Matthew Thomas has written a summary of this event for PET's flagship publication BioNews, and James Heather has written a summary of this event for the Wellcome Trust's blog. Panel speaker Kerry Andrew discusses the themes of the event in her BioNews article 'BRCA and I', while journalist and filmmaker Tessa Mayes quotes several of the panel speakers here.
When the actress Angelina Jolie wrote publicly about her decision to undergo a prophylactic double mastectomy, breast cancer captured the world's attention. Jolie opted for the procedure because of the breast cancer risk posed by a BRCA1 gene mutation she carries, and the fact that her mother and grandmother died from cancer. Jolie is still being widely praised for having promoted awareness and understanding of breast cancer, but her case raises two questions. First, to what extent was her situation representative - either of women in general, or of people who are predisposed to develop breast cancer? Second, to what extent was her response to her situation proportionate?
Breast cancer is a common form of cancer in women (and a rare form of cancer in men), but only a small minority of cases are thought to be caused by highly penetrant inherited mutations in a single gene. More than half of these cases are caused by mutations in the BRCA1 or BRCA2 genes, which also greatly increase the risk of ovarian cancer. BRCA genes aren't the whole story, however - nine non-BRCA genes linked to breast cancer are currently being tested for as part of the Mainstreaming Cancer Genetics programme, and an inherited predisposition to breast cancer may involve many genes rather than just one. Genetics may also affect people's responsiveness to breast cancer prevention and treatment, thereby opening up possibilities for tailoring prevention and treatment to individuals or groups (personalised medicine).
Counselling is available to women deciding what - if anything - to do if they are at increased risk of breast cancer. Mastectomy (removal of one or both breasts) and oophorectomy (removal of one or both ovaries) are two drastic preventative options, among several options that are available to patients in a similar predicament to Jolie. Among the less drastic options is one that has been recommended by the National Institute for Health and Care Excellence - that healthy women over 35 at high risk of breast cancer should be offered preventative drug therapy, something that has not happened previously outside of clinical trials.
This event saw these and other aspects of breast cancer discussed in relation to genetics and risk, from contrasting perspectives, by a panel of experts.

  Speakers:
Kerry Andrew
Patient and carrier of a BRCA1 gene mutation
Diana Eccles
Professor of Cancer Genetics and Director of the Clinical Trials Unit at the University of Southampton
Gareth Evans
Professor of Medical Genetics and Cancer Epidemiology at the University of Manchester, and Consultant in Medical Genetics and Cancer Epidemiology at the Christie and Central Manchester University Hospitals NHS Foundation Trusts
Baroness Delyth Morgan
Crossbench Peer in the House of Lords, Chief Executive of Breast Cancer Campaign and former Chief Executive of Breakthrough Breast Cancer
Gordon Wishart
Consultant Breast and Endocrine Surgeon, Visiting Professor of Cancer Surgery at Anglia Ruskin University and former Director of the Cambridge Breast Unit at Addenbrooke's Hospital

  Chair:
Dr Christine Patch
Consultant Genetic Counsellor and Manager at Guy's and St Thomas' NHS Foundation Trust, and former Chair of the British Society for Genetic Medicine

  Partners and supporters:
  Wellcome Trust

FROZEN ASSETS?
Preserving Sperm, Eggs and Embryos

FREE event
Edinburgh
25 October 2016

BOOK HERE

Datalabel The UK's Leading Supplier Of Medical Labels & Asset Labels
 

RETHINKING THE ETHICS OF EMBRYO RESEARCH
Genome Editing, 14 Days and Beyond

Public Conference
London
7 December 2016

Speakers include

Professor Magdalena Zernicka-Goetz

Dr Kathy Niakan

Professor Sir Ian Wilmut

Lord George Carey

Baroness Mary Warnock

Dr Simon Fishel

Professor Bruce Whitelaw

Professor Alison Murdoch

Professor David Jones

Professor Sarah Franklin

Professor Stephen Wilkinson

BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation

Advertising & sponsorship
Terms & conditions
Sitemap

Progress Educational Trust, 140 Grays Inn Road, London WC1X 8AX, UK
Tel: +44 (0)20 7278 7870 Email:
Limited company registered in England and Wales no 7405980
Registered charity no 1139856

Website developed and built by Face to Face
Website designed by Thunder
Website administration

© 1992, 2016
Progress Educational Trust